Collectively, our study identifies the clinical value of VSIG4 blockade in reshaping the immune microenvironment of immunosuppressive tumours and provides a novel perspective for understanding the role of TAMs in modulating anti‐tumour immunity. Here, VSIG4 is linked to neoplasm.